Literature DB >> 20443775

Prodrug design of phenolic drugs.

J M Férriz1, J Vinsová.   

Abstract

Phenolic group in therapeutic drugs can be used for a prodrug modification to overcome various undesirable drug properties that may become pharmacological, pharmaceutical or pharmacokinetic barriers for application. Several strategies have been used in order to overcome the limited bioavailability of phenolic drugs. Classical design represents a nonspecific chemical approach to mask undesirable drug properties, limited bioavailability or chemical instability. Targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrug to specific enzyme or specific membrane transporter has potential as selective drug delivery system mainly in cancer therapy. The article brings examples of ester, sulphate, carbamate, carbonate, phosphate and ether prodrugs as well as the limitations of these prodrug strategies. Some specific enzyme targets are also presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443775     DOI: 10.2174/138161210791293042

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

Review 1.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

3.  Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.

Authors:  Ivan S Alferiev; Radhika Iyer; Jamie L Croucher; Richard F Adamo; Kehan Zhang; Jennifer L Mangino; Venkatadri Kolla; Ilia Fishbein; Garrett M Brodeur; Robert J Levy; Michael Chorny
Journal:  Biomaterials       Date:  2015-02-16       Impact factor: 12.479

4.  Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription.

Authors:  Jiangling Peng; Mark Miller; Bingbing X Li; Xiangshu Xiao
Journal:  ACS Med Chem Lett       Date:  2022-02-17       Impact factor: 4.632

5.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

6.  SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization.

Authors:  Zilei Liu; Jie Li; Suhua Li; Gencheng Li; K Barry Sharpless; Peng Wu
Journal:  J Am Chem Soc       Date:  2018-02-16       Impact factor: 15.419

7.  Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics.

Authors:  Yingchao Li; Yongjun Wang; Ran Zhang; Cuiru Liu; Yue Wei; Jin Sun; Zhonggui He; Youjun Xu; Tianhong Zhang
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

8.  Amino Acid Carbamates As Prodrugs Of Resveratrol.

Authors:  Andrea Mattarei; Michele Azzolini; Martina La Spina; Mario Zoratti; Cristina Paradisi; Lucia Biasutto
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

9.  Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.

Authors:  Morten Rohde; Niels M Rk; Anders E Håkansson; Klaus G Jensen; Henrik Pedersen; Tina Dige; Erling B J Rgensen; René Holm
Journal:  Results Pharma Sci       Date:  2014-05-02

Review 10.  Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunya.

Authors:  Anjali Soni; Khushhali M Pandey; Pratima Ray; B Jayaram
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.